Note 2 - Selected Balance Sheet Data (Details Textual) $ in Thousands |
3 Months Ended |
6 Months Ended |
|
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2016
USD ($)
|
Dec. 31, 2015
USD ($)
|
Jun. 30, 2016
USD ($)
|
| Available-for-sale Securities |
$ 56,600
|
$ 56,600
|
|
$ 31,600
|
| Payments to Acquire Available-for-sale Securities |
|
1,625
|
|
|
| Inventory, Net |
66,089
|
66,089
|
|
57,102
|
| Inventory Valuation Reserves |
24,000
|
24,000
|
|
|
| Other Assets, Noncurrent |
42,694
|
42,694
|
|
1,922
|
| Payments to Acquire Investments |
|
$ 40,000
|
|
|
| Number of Reporting Units |
|
3
|
|
|
| Astute Medical, Inc. [Member] |
|
|
|
|
| Payments to Acquire Investments |
40,000
|
|
|
|
| ChemoCentryx, Inc (CCXI) [Member] |
|
|
|
|
| Available-for-sale Equity Securities, Gross Unrealized Gain |
|
$ 17,700
|
|
|
| Available-for-sale Equity Securities, Amortized Cost Basis |
29,500
|
29,500
|
|
29,500
|
| Certificates of Deposit [Member] | CHINA |
|
|
|
|
| Payments to Acquire Available-for-sale Securities |
|
1,300
|
|
|
| Advanced Cell Diagnostics (ACD) [Member] |
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory |
|
|
|
$ 9,600
|
| Advanced Cell Diagnostics (ACD) [Member] | Available-for-sale Securities [Member] |
|
|
|
|
| Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities |
$ 5,100
|
$ 5,100
|
|
|